Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab

Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab

IntroductionGiven the varying severity of coronavirus disease 2019 (COVID-19) and the rapid spread of Severe-Acute-Respiratory-Syndrome-Corona-Virus-2 (SARS-CoV-2), vaccine-mediated protection of particularly vulnerable individuals has gained increasing attention during the course of the pandemic.Me...

Full description

Bibliographic Details
Main Authors: Saskia Räuber, Alice Willison, Melanie Korsen, Tristan Kölsche, Kristin S. Golombeck, Benedikt Plaack, Julia Schüller, Niklas Huntemann, Leoni Rolfes, Christina B. Schroeter, Christopher Nelke, Liesa Regner-Nelke, Moritz Förster, Marius Ringelstein, Michael Harry Barnett, Hans-Peter Hartung, Orhan Aktas, Philipp Albrecht, Tobias Ruck, Nico Melzer, Sven G. Meuth, David Kremer
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Immunology
Subjects:
SARS-CoV-2
COVID-19
vaccination
multiple sclerosis
ocrelizumab
B cell response
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1037214/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1037214/full

Similar Items